All In Biotech

Drug Trial Radar · NCT00690794

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution

Last checked: Nov 19, 2026Latest source record: Jul 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 726 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

726

Actual

Start

Jul 2008

Primary completion

May 2009

Study completion May 2009

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Jun 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.

Conditions

  • Open-angle Glaucoma
  • Ocular Hypertension

Interventions

  • Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)Drug

    Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.

  • Latanoprost ophthalmic solution 0.005% (XALATAN®)Drug

    Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) ScoreTime frame: Baseline, Day 90

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.